AM
Alan Menter

Elite Scholar

535
Works
41,060
Citations
97
H-Index
Search Authors
Author Statistics
External Links
OpenAlex Profile ORCID Profile

Alan Menter

Also known as: A MENTER, A Menter, A. Menter, Alan Menter, Alan Menter, MD

535

Total Works

41,060

Citations

97

H-Index

306

i10-Index

Citation & Works Trend by Year
47 years active
Top Research Topics
Psoriasis: Treatment and Pathogenesis (405) Dermatology and Skin Diseases (373) Spondyloarthritis Studies and Treatments (308) Rheumatoid Arthritis Research and Therapies (23) Genetic and rare skin diseases. (18)
Recent Publications
15 shown
Year Publication Title Citations Action
2024 Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMitless trial) Journal of the European Academy of Dermatology and Venereology 20
2023 Response to letter to the editor “It’s time to consider a new topical algorithm for psoriasis” Journal of the American Academy of Dermatology 0
2023 Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial Dermatology and Therapy 0
2023 43851 Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials Journal of the American Academy of Dermatology 0
2023 IL-17 and -23 Inhibitors for the Treatment of Psoriasis EMJ Allergy & Immunology 11
2023 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial SKIN The Journal of Cutaneous Medicine 0
2023 Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program SKIN The Journal of Cutaneous Medicine 3
2022 Biologics for psoriasis: is there any unmet need left? Expert Opinion on Biological Therapy 3
2022 Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial SKIN The Journal of Cutaneous Medicine 0
2022 Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program SKIN The Journal of Cutaneous Medicine 8
2022 33221 Further clinical outcomes in patients with moderate-to-severe chronic plaque psoriasis receiving adalimumab reference product continuously or switching between BI 695501 and adalimumab RP in the phase III, randomized, interchangeability VOLTAIRE-X trial Journal of the American Academy of Dermatology 2
2022 Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial American Journal of Clinical Dermatology 32
2022 Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis Dermatology and Therapy 23
2022 Cryptococcal meningitis associated with interleukin‐17 inhibitor use for psoriasis Dermatologic Therapy 3
2022 Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP) Dermatology and Therapy 10

Data source: OpenAlex API